Thursday 7 May, 2026
Introduction: Worldwide >50 million individuals are estimated to be chronically infected with hepatitis C virus (HCV), with ~1.0 million new…
Read morePoster: Drug/Disease Modelling - Infection
THE TRANSLATIONAL ZEBRAFISH LARVAE FRAMEWORK ACCURATELY PREDICTS BEDAQUILINE’S CLINICAL EARLY BACTERICIDAL ACTIVITY AGAINST TUBERCULOSIS
Thursday 7 May, 2026
Introduction: Tuberculosis (TB) is a leading cause of death worldwide[1]. Translational pharmacometrics is vital to accelerate the development of novel…
Read moreHost Immunity as a Bidirectional Regulator of Phage Therapy: A Mechanism-Based PKPD Modeling Approach
Thursday 7 May, 2026
Objectives Bacteriophage therapy in immunocompetent hosts is governed not only by phage replication and bacterial dynamics, but also by host…
Read moreDrug interaction between pyrazinamide and standard- and high-dose rifampicin
Thursday 7 May, 2026
Background and objective: Pyrazinamide is an essential component of the first-line combination treatment for drug-susceptible tuberculosis (TB), taken by approximately…
Read morePopulation pharmacokinetics–driven optimization of CFU-reduction study design for boosted ethionamide combinations in mice
Thursday 7 May, 2026
Objectives: Ethionamide (Eto) is used in combination regimens for pulmonary multidrug-resistant tuberculosis (MDR-TB), with known poor tolerability. Alpibectir is currently…
Read moreLATE TREATMENT INITIATION LEADS TO REDUCED ANTIVIRAL POTENCY OF NIRMATRELVIR AND GS-441524 AGAINST IN VITRO SARS-COV-2 INFECTION
Thursday 7 May, 2026
Introduction: The timing of initiation is critical in antiviral treatment. Viral dynamic (VD) modeling is widely used to study the…
Read moreJoint mechanistic modeling of viral and antibody responses to vaccines in Non-Human Primates to quantify SARS-CoV-2 mechanistic correlate of protection.
Thursday 7 May, 2026
Introduction and objectives: SARS-CoV-2 evolves constantly and rapidly. The identification of correlates of protection (CoPs) against the pathogen could accelerate…
Read moreASSESSMENT OF PIPERACILLIN–TAZOBACTAM VARIABILITY IN OBESITY THROUGH POPULATION PHARMACOKINETIC MODELING
Thursday 7 May, 2026
Introduction/Objectives: Over the past decades, the prevalence of obesity has risen at an alarming rate worldwide [1]. Obesity is commonly…
Read morePopulation Pharmacokinetic Model of Tebipenem (TBP) in Blood and Plasma after Oral Administration of Tebipenem Pivoxil (TBP-PI) in Adult Participants.
Thursday 7 May, 2026
Introduction: Tebipenem pivoxil (TBP-PI) is an orally bioavailable carbapenem prodrug that is rapidly converted in vivo to the active moiety,…
Read morePharmacokinetic and pharmacodynamics of BTZ-043 in patients with pulmonary tuberculosis
Thursday 7 May, 2026
Objectives BTZ-043, a drug candidate currently under investigation for treatment of tuberculosis (TB), inhibits cell wall synthesis of mycobacteria by…
Read more